What is Infliximab-dyyb?

Category: Prescription Drugs

Most popular types: Inflectra


Infliximab-dyyb is a medication that is considered biosimilar to infliximab, a monoclonal antibody used in the treatment of a number of autoimmune conditions, including: Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe 0
Moderate 0
Mild 0
None 1

Commonly reported side effects and conditions associated with Infliximab-dyyb

Side effect Patients


Based on patients currently taking Infliximab-dyyb

Dosage Patients
100 mg every 8 weeks 1
100 mg every 6 weeks 1
500 mg every 8 weeks 1
100mg as needed 1


Currently taking Infliximab-dyyb

Duration Patients
1 - 6 months 3
6 months - 1 year 1
Adherence Evaluations
Always 1
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden Evaluations
Very hard to take 0
Somewhat hard to take 0
A little hard to take 0
Not at all hard to take 1

What people switch to and from

Patients started taking Infliximab-dyyb after stopping:

Treatment Patients
Hydroxychloroquine (Plaquenil) 1
Vedolizumab (Entyvio) 1
Last updated:
There are no evaluations for Infliximab-dyyb.